Corneal neovascularization (NV) is a sight-threatening condition usually associated with inflammatory or infectious disorders of the ocular surface. It has been shown in the field of cancer angiogenesis research that a balance exists between angiogenic factors (such as fibroblast growth factor and vascular endothelial growth factor) and anti-angiogenic molecules (such as angiostatin, endostatin, or pigment epithelium derived factor) in the cornea. Several inflammatory, infectious, degenerative, and traumatic disorders are associated with corneal NV, in which the balance is tilted towards angiogenesis. The pathogenesis of corneal NV may be influenced by matrix metalloproteinases and other proteolytic enzymes. New medical and surgical treatments, including angiostatic steroids, nonsteroidal inflammatory agents, argon laser photocoagulation, and photodynamic therapy have been effective in animal models to inhibit corneal NV and transiently restore corneal "angiogenic privilege." Curr Opin Ophthalmol 2001, 12:242-249 Neovascularization (NV) is the formation of new vascular structures in areas that were previously avascular. Two possibly overlapping mechanisms may be involved in neovascularization processes [1,2]: vasculogenesis, the formation of new blood vessels from bone marrowderived angioblasts, mainly during embryogenesis, and angiogenesis, the formation of new vessels from preexisting vascular structures. The latter is the common mechanism in tumor growth and in corneal and retinal disorders, which occurs when the balance between angiogenic and anti-angiogenic factors is tilted towards angiogenic factors [3]. We review corneal disorders associated with neovascularization, the molecular basis of this complication, and potential therapies for these disorders.
The blood supply of the cornea arises from the ciliary arteries, which are branches of the ophthalmic artery that divide and end in the pericorneal plexus in the limbus area. Corneal NV involves the sprouting of new vessels, essentially from capillaries and venules of the pericorneal plexus [4, 5] . Two clinical entities of corneal NV can be discerned: stromal NV, which is associated primarily with stromal keratitis, and the vascular pannus, which is composed of connective tissue proliferating in the superficial corneal periphery and is associated mainly with ocular surface disorders [6] . Although NV may involve several corneal layers, a recent study has shown that the main localization of vascularized corneal buttons is in the upper-and mid-third areas of the anterior stroma [7].
Corneal neovascularization: epidemiology and risk factors
Neovascular and infectious diseases of the cornea and other parts of the eye represent a major public health problem. It is estimated that for a given year, 1.4 million patients in the US may develop corneal NV; 4% of the US population has corneal NV; and 20% of corneal specimens obtained during corneal transplantation show histopathologic evidence of vascularization [8] . A wide range of inflammatory, infectious, degenerative, or traumatic disorders may induce corneal neovascularization (Table 1) . This major ocular complication can lead to corneal scarring, edema, lipidic deposition, and inflammation that may not only significantly alter visual acuity, but also worsen the prognosis of subsequent penetrating keratoplasty (PK). Among histopathologic diagnoses of vascularized corneal buttons after PK, graft failure represented more than 30% of the buttons [7] . This is con-sistent with studies that reported the poor prognosis of vascularized grafts [9] . Risk factors of corneal NV after PK have been assessed in patients without active inflammation, previous corneal NV, or persistent epithelial defects [10] . Results from this prospective study showed a significantly higher risk of corneal NV when suture knots were buried in the host stroma, when active blepharitis was present, or when a large recipient bed was used. Additionally, 6 to 9 months after PK, 41% of treated eyes developed corneal NV, showing the significance of this complication in relatively low-risk corneas.
Immunologic and infectious disorders of the cornea and conjunctiva may encompass the production of angiogenic molecules responsible for corneal NV. Accordingly, longterm follow-up of patients with inflammatory disorders, such as atopic keratoconjunctivitis, revealed that the rate of corneal NV may be as high as 60% during the course of disease [11] . Among the different infectious agents that induce corneal vascularization, the herpes virus family (mostly Herpes simplex and Herpes zoster) remains the primary cause of keratitis-induced NV in PK buttons. This complication occurs after interstitial, necrotizing, or recurrent keratitis and is not dependent solely on the host reaction. Experimental data have shown that ocular disease patterns induced by Herpes simplex virus are genetically determined by viral DNA [12] .
Although it occurs mainly during inflammatory processes, corneal NV may occur in degenerative (including pterygium and Terrien marginal degeneration) and congenital (aniridia) disorders [7,13-17]. However, even in these conditions, inflammation may be involved in the pathogenesis of corneal NV [18, 19] . Although all infectious keratitis may induce the formation of corneal NV, Acanthamoeba keratitis has been reported to lack corneal NV even in relatively severe and long-standing cases [20] . Although neovascularized corneas have been depicted infrequently in this disease, the relative lack of stromal NV underscores the complex balance between angiogenic and anti-angiogenic molecules present in the cornea. Therefore, this "angiogenic privileged" site has been used to study the molecular basis of angiogenesis in vivo and in vitro. Corneal avascularity requires low levels of angiogenic factors and high levels of anti-angiogenic factors under basal conditions. Rupture of this homeostasis may occur in the pathogenesis of corneal NV.
Corneal angiogenesis: molecular basis Corneal avascularity: balance between angiogenesis and anti-angiogenesis
Angiogenesis occurs in tissue when the balance between angiogenic and anti-angiogenic factors is tilted towards angiogenic molecules. This premise summarizes the current research in angiogenesis. Accordingly, NV requires not only the up-regulation of angiogenic factors, but also the down-regulation of anti-angiogenic factors [21] . The cornea has been used as a model to study angiogenic and anti-angiogenic molecules in vivo (Table 2 ).
Angiogenic molecules involved in corneal neovascularization

Vascular endothelial growth factor
During corneal NV, an up-regulation of angiogenic factors must be present, most likely in association with a down-regulation of anti-angiogenic molecules. It was recently shown that vascular endothelial growth factor (VEGF) was up-regulated in inflamed and vascularized corneas in humans and in animal models [22, 24] . VEGFs are secreted growth factor peptides generated by alternative splicing in five isoforms (VEGF115, VEGF121, VEGF 165, VEGF 189, and VEGF 206) [25] . Mainly produced by macrophages-T cells, retinal pigment epithelial cells, astrocytes, and smooth muscle cells-induction of VEGF has been shown in hypoxia and inflammatory situations. Additionally, VEGF promotes several steps of angiogenesis, including proteolytic activities (dissolution of the membrane of the original vessel), endothelial cell proliferation, migration, and capillary tube formation. Interestingly, requirement of VEGF in corneal angiogenesis was shown by the inhibition of NV after stromal implantation of an anti-VEGF blocking antibody in a rat model [26] . This result has been reproduced using a VEGF blocking peptide in a rabbit corneal model [27]. 
Fibroblast growth factor
Another angiogenic factor, basic fibroblast growth factor (bFGF), has been used extensively in corneal angiogenesis models. Basic fibroblast growth factor belongs to the fibroblast growth factor family. This family encompasses 23 structurally related heparin-binding peptides that are widely expressed in developing and adult tissues during cellular differentiation, angiogenesis, mitogenesis, and wound repair. FGF function is mediated by binding its cognate receptors (FGFR-1, -2, -3, and -4). FGF-1 is expressed in the normal corneal epithelium, and FGF-2 is up-regulated after injury and in a keratocyte-vascular endothelial cell coculture [28] . Interestingly, bFGF binds Bowman and Descemet membranes in normal corneas and vascular basement membranes in neovascularized corneas. According to the degree of maturation of the new vessels, different intensities of binding were detected in normal limbal and newly formed corneal vessels [29] . This binding, probably to heparan sulfate proteoglycans, emphasizes the role of the extracellular matrix (ECM) in the regulation of corneal angiogenesis.
Matrix metalloproteinases
Extracellular matrix turnover associated with wound healing is usually accompanied by angiogenesis in granulation tissue. One feature of corneal wound healing is the lack of this vascular reaction. Matrix metalloproteinases 
Anti-angiogenic molecules and corneal neovascularization
Several anti-angiogenic molecules have been either detected or tested in the cornea. These anti-angiogenic factors may be derived from larger precursors by proteolytic cleavage or directly produced in their active forms.
Angiostatin
Angiostatin, a 38 kDa proteolytic fragment of plasminogen, is a potent anti-angiogenic factor [40]. The fragment was first isolated from a Lewis lung carcinoma cell line and was found to inhibit vascular endothelial cell proliferation and migration. In the eye, implantation of angiostatin and angiostatin-like fragments inhibits corneal NV induced by bFGF or angiogenin [41, 42] . Several lines of evidence suggest corneal production of angiostatin [43-45]: 1) extra-hepatic synthesis of plasminogen has been shown in corneal epithelium [46] , 2) angiostatin has been isolated in the tear film of contact lens bearing patients (induced by hypoxia) [47] , and 3) all the MMPs responsible for angiostatin production (MMP-2, -3, -7, -9,and -12) have been detected in the cornea [31-35].
Endostatin
Endostatin, another anti-angiogenic factor, is a 20 kDa proteolytic fragment of collagen XVIII [48]. Endostatin has been isolated from the conditioned medium of a murine hemangioendothelioma cell line and has been shown to inhibit FGF-2 and VEGF induced vascular endothelial cell migration and proliferation in vitro and to reduce tumor progression in mice [48] . Collagen type XVIII is a nonfibrillar collagen localized mainly to the vascular and epithelial basement membrane. In the eye, collagen XVIII has been localized to the retina (inner limiting membrane and pigment epithelium), the lens capsule, and the cornea [49,50]. Cleavage of collagen types XVIII by proteases (including MMPs, cathepsin L, and elastase) generates endostatin-like fragments that may display anti-angiogenic properties [51] . Endostatin implanted in the cornea showed an inhibition of bFGFinduced neovascularization [52] . Additionally, local production of endostatin may occur during corneal wound healing as the cleaving enzymes and the substrate (collagen XVIII) are present in the basement membrane area during this process. Several anti-angiogenic factors derived from collagens also have been described, including restin, arresten, canstatin, and tumstatin, but their role in corneal angiogenesis has not been characterized fully [53] .
Pigment epithelium derived factor
Pigment epithelium derived factor (PEDF) is a potent anti-angiogenic and neurotrophic factor that was first identified in retinoblastoma cells and then characterized in pigmented epithelium of the retina, iris, and cornea [54] . Although PEDF belongs to the serine protease inhibitor (serpin) family, it does not have any known substrate. Its role in corneal angiogenesis has been shown recently. Blocking antibodies against PEDF produce corneal vascularization when implanted in rat corneal stroma. Additionally, removal of PEDF from human stromal extracts suppresses the inhibition of vascular endothelial cell migration induced by these extracts. Furthermore, recombinant PEDF inhibits corneal NV induced by implantation of bFGF pellets [55] . Additional investigations will be needed to further assess the role of this molecule in diseased corneas.
Treatments
Corneal NV is often accompanied by decreased visual acuity caused by stromal edema, lipidic deposits, causal keratitis, or scarring, which leads the physician to evaluate medical and/or surgical therapies (Table 3) .
Medical treatment
Topical corticosteroids remain the main treatment for suppressing actively proliferating corneal vessels [56] [57] [58] [59] . The anti-angiogenic effect of steroids is believed to be a result of their anti-inflammatory properties, including inhibition of inflammatory cell chemotaxis, and their inhibition of the synthesis of pro-inflammatory cytokines. Steroids also directly inhibit vascular endothelial cell proliferation and migration [59] [60] [61] [62] [63] [64] .
Prostaglandins are produced in corneal wound-healing and angiogenesis. Inhibition of their synthesis with either phospholipase A2 or cyclooxygenase (COX) inhibitors (steroidal or non-steroidal anti-inflammatory agents, respectively) significantly reduces corneal angiogenesis in animal models of corneal NV [65] [66] [67] [68] .
Non-steroidal anti-inflammatory agents are commonly used in the management of ocular surface disorders. Two types of COX enzymes have been found in the cornea, the constitutive COX-1 and the inducible COX-2. Treatment with selective inhibitors has assessed their differential significance in corneal angiogenesis. Selective inhibition of COX-2 has a 20% inhibition rate of basal prostaglandin E2 (PGE2) corneal synthesis, and this inhibition rate rises to 80% after wounding [69] . Furthermore, selective COX-2 inhibition significantly inhibits corneal NV with a similar anti-angiogenic effect to indometacin, a nonselective COX-1 and -2 inhibitor. Various other research molecules have shown anti-angiogenic activity in corneal NV, including topical application of IL-1 receptor antagonist [70] , octreotide (a long-acting somatostatin analogue) [71] , cyclosporine A [72] , FK 506 [73] , plasminogen fragments [41, 42, 74] , spironolactone [75] , thalidomide [76] , amiloride [77] , curcumin [36, 78] and PAF antagonist [79] . However, because medical treatment is most efficient in actively growing NV, many investigators are exploring the surgical management of corneal NV; the research is aimed not only at preventing PK in high-risk patients, but also at lengthening the survival rate of a required PK.
Surgical treatment
The first line of this investigation has been to occlude the vessels with the use of different techniques, including argon laser, electro-coagulation, and photodynamic therapy. Laser photocoagulation using a 577 nm yellow dye has been assessed for treating established corneal NV. The technique seems to be relatively safe in animal studies [80, 81] and has been subsequently tested in humans in clinically significant corneal NV (resistant to medical therapy), before PK (to prevent recurrence of corneal NV), and after PK (to treat corneal NV). Although there has been some reduction in the NV area in clinically significant corneal NV and after PK, the role of corneal laser photocoagulation for preoperative treatment of high-risk keratoplasty remains unclear, and the technique does not seem to be useful in extensive corneal NV [82, 83] .
A fine needle diathermy technique, using 3/8 circle side cutting stainless steel needles (from 10-0 monofilament black nylon suture) and a unipolar diathermy unit, is an interesting alternative to laser photocoagulation in humans [84] . This technique enabled the occlusion of 50 to 100% of corneal NV with a moderate benefit in visual acuity in 14 patients. After a follow-up of 6-24 months, none experienced significant side effects.
Photodynamic therapy is another method in which a photosensitizer is injected into systemic circulation or topically administered on the ocular surface. This photosensitizer accumulates in new vessels and is subsequently activated by a laser beam to selectively occlude new vessels. This technique, used for choroidal NV, is under investigation in animal models of corneal NV. Preliminary studies have shown promising results in rabbits. Histological studies of treated corneas revealed corneal NV thrombosis and severely injured vascular endothelial cells [85] [86] [87] [88] [89] . Further investigations are required to assess the benefit-risk ratio of this procedure.
Also under investigation is restoration of the ocular surface with the use of conjunctival, limbal, or amniotic membrane transplantation to reduce the angiogenic stimuli. Evaluations of auto-and allograft conjunctival transplantation, in the treatment of uni-and bilateral ocular surface disorders, have shown decreased corneal neovascularization [90] . Additionally, amniotic membrane transplantation has been shown to have antiangiogenic properties [91] . Moreover, anti-angiogenic molecules and precursors (including thrombospondin I and collagen XVIII) have been detected in amniotic membranes and may play a role in this mechanism [92] [93] [94] . The treatment of severe ocular surface disorders with corneal ulceration, neovascularization, and conjunctival metaplasia may require limbal autograft transplantation. This technique has been used successfully in vascularized corneas. It is thought to act by a double mechanism: by treating the stem cell deficiency and therefore treating the angiogenic stimulus provided by chronical corneal ulceration (Table 4) , and by directly inhibiting vascular endothelial cells [95] .
However, although these molecules and surgical therapeutics have shown efficiency in treating corneal NV, they do not prevent the physician from treating the underlying cause of corneal NV with antibiotic or antiviral therapy for infectious keratitis, suture or contact lens removal for iatrogenic corneal NV, lubrication and prolonged eyelid hygiene for meibomian gland dysfunction, avoidance of allergens in the context of atopic dermatitis, and systemic immunosuppressive therapy for severe ocular cicatricial pemphigoid.
An ideal anti-angiogenic therapy should be effective against actively growing and established corneal NV, inexpensive, lacking in side effects, and tested in a randomized prospective clinical study. Further investigations are needed to place these medical and surgical treatments alongside corneal NV therapeutics.
